Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (139)	9/18/2006 9:50:37 AM
From: david nordic	Read Replies (1) \| Respond to of 507

Nektar's Amphotericin B Inhalation Powder (ABIP) Press Release Source: Nektar Therapeutics European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk Monday September 18, 8:30 am ET SAN CARLOS, Calif.--(BUSINESS WIRE)--Sept. 18, 2006--Nektar Therapeutics (Nasdaq:NKTR - News) announced today that its Amphotericin B Inhalation Powder (ABIP) product has been granted orphan medicinal product designation by the European Commission for the prevention of pulmonary fungal infections in patients deemed at risk. This designation is based on a recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA). ADVERTISEMENT "Prevention of these serious fungal infections in the lung is a major priority, given the increasing incidence of invasive pulmonary aspergillosis in immunosuppressed patients," said Dr. David Denning, professor of medicine and medical mycology at the University of Manchester. "Any therapy that reduces the incidence of invasive pulmonary aspergillosis in particular is welcome, as these infections are frequently fatal, and can be expensive to treat." According to the EMEA, orphan medicinal products are for diagnosing, preventing or treating life-threatening or very serious conditions that are rare and affect less than five of every 10,000 persons in the European Union (EU). An orphan drug designation provides 10 years of potential market exclusivity if the product candidate is approved for marketing in the EU. It also allows for regulatory assistance in preparing the marketing application, free protocol assistance to optimize clinical development, reduced regulatory fees associated with applying for marketing approval and direct access to the centralized procedure for Marketing Authorization Application through the EMEA. "We are pleased to make continued progress in our ABIP program and look forward to using the scientific guidance and assistance available through the EMEA's Orphan Medicinal Drug Program," said David Johnston, Nektar senior vice president of research and development. "ABIP holds the promise of preventing fatal fungal infections that start in the lungs, can be very difficult to treat, and are associated with extremely high mortality rates in spite of currently available treatments." In the U.S., the Food and Drug Administration (FDA) granted both Fast Track designation and Orphan Drug designation to ABIP for prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy. About Amphotericin B Inhalation Powder (ABIP) ABIP is under development for the prevention of pulmonary fungal infections such as aspergillosis in high-risk immunosuppressed patients. The product is designed to target the site of infection directly with a novel formulation of amphotericin B, a broad spectrum, fungicidal drug. Nektar's innovative formulation and pulmonary delivery method could potentially eliminate systemic, dose-limiting toxicities found with current formulations of amphotericin B that are delivered intravenously. Immunosuppressed patients, for example, those receiving organ or stem cell transplants, or chemotherapy or radiation therapy for hematologic malignancies -- are vulnerable to opportunistic fungal infections, such as aspergillosis, which start in the lungs and spread throughout the body. Aspergillosis has a mortality rate of over 50%, and in some immunosuppressed patient groups the mortality rate may be near 100%.(1) Using ABIP for patients at risk of developing the infection may potentially reduce the incidence of these infections, as well as associated high morbidity and mortality and significant treatment costs. ABIP recently completed a multi-dose, dose escalation clinical study in preparation for pivotal trials to begin in 2007. (1) Lin et al. 2001, Aspergillosis Case-Fatality Rate: Systematic Review of the Literature. Clinical Infectious Disease, 32: 358-366. NOTE TO EDITORS: Information on ABIP data presented at major congresses by Nektar scientists is available by contacting Nektar Corporate Communications at 650-631-4954.